Affiliation:
1. Institute of Biophysics, National Research Council, Via Moruzzi 1, 56124 Pisa,Italy
2. Department of Food and Drug, University of Parma, Parco Area delle Scienze 23/A, 43124 Parma,Italy
Abstract
:
The development of safe and efficacious enzyme-based human therapies has increased
greatly in the last decades, thanks to remarkable advances in the understanding of
the molecular mechanisms responsible for different diseases, and the characterization of the
catalytic activity of relevant exogenous enzymes that may play a remedial effect in the
treatment of such pathologies. Several enzyme-based biotherapeutics have been approved
by FDA (the U.S. Food and Drug Administration) and EMA (the European Medicines
Agency) and many are undergoing clinical trials. Apart from enzyme replacement therapy in
human genetic diseases, which is not discussed in this review, approved enzymes for human
therapy find applications in several fields, from cancer therapy to thrombolysis and the
treatment, e.g., of clotting disorders, cystic fibrosis, lactose intolerance and collagen-based
disorders.
The majority of therapeutic enzymes are of microbial origin, the most convenient source due
to fast, simple and cost-effective production and manipulation. The use of microbial recombinant
enzymes has broadened prospects for human therapy but some hurdles such as high
immunogenicity, protein instability, short half-life and low substrate affinity, still need to be
tackled. Alternative sources of enzymes, with reduced side effects and improved activity, as
well as genetic modification of the enzymes and novel delivery systems are constantly
searched. Chemical modification strategies, targeted- and/or nanocarrier-mediated delivery,
directed evolution and site-specific mutagenesis, fusion proteins generated by genetic manipulation
are the most explored tools to reduce toxicity and improve bioavailability and
cellular targeting.
This review provides a description of exogenous enzymes that are presently employed for the
therapeutic management of human diseases with their current FDA/EMA-approved status,
along with those already experimented at the clinical level and potential promising candidates.
Funder
bilateral project of the National Research Council of Italy
Russian Foundation for Basic Research
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献